## Appendix

Appendix Table 1: List of ‘Other’ ILD subtypes

|  |  |
| --- | --- |
| ILD Subtype | N (%) |
| Idiopathic Interstitial Pneumonias |  |
| * Non-specific interstitial pneumonia (NSIP) | 16 (13.1) |
| * Desquamative interstitial pneumonia (DIP) | 2 (1.6) |
| * Cryptogenetic organizing pneumonia (COP) | 2 (1.6) |
| Hypersensitivity pneumonitis (exogen allergic alveolitis) | 25 (20.5) |
| Rheumatic and connective tissue diseases with pulmonary involvement | 5 (4.1) |
| Drug-related | 3 (2.5) |
| Combined pulmonary fibrosis and emphysema (CPFE) | 5 (4.1) |
| Other Forms |  |
| * Pulmonary hymphangioleiomyomatosis | 7 (5.7) |
| * Pulmonary Langerhans cell histocytosis | 2 (1.6) |
| * Pulmonary alveolar proteinosis | 2 (1.6) |
| Others | 35 (28.7) |
| Not classifiable | 18 (14.8) |

Appendix Table 2: Influencing factors on medical costs at baseline across ILD subtypes in complete cases

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | IPF | Fibrosing ILD | Sarcoidosis | Other |
|  | OR [95% CI] | OR [95% CI] | OR [95% CI] | OR [95% CI] |
| Male | 0.04 [0.00 - 0.47] | 1.05 [0.77 - 1.34] | 1.47 [1.25 - 1.69]\* | 1.74 [1.33 - 2.15]\* |
| Former/Current smoker | 2.14 [1.85 - 2.42]\* | 0.41 [0.00 - 0.83] | 0.67 [0.00 - 1.41] | 0.92 [0.85 - 0.99]\* |
| Age | 0.93 [0.91 - 0.95]\* | 1.04 [1.03 - 1.06]\* | 0.96 [0.95 - 0.96]\* | 1.02 [1.01 - 1.03]\* |
| FVC % pred. At baseline | 0.93 [0.91 - 0.95]\* | 0.99 [0.98 - 1.00] | 1.00 [1.00 - 1.00] | 0.99 [0.99 - 1.00] |
| Disease duration | 1.23 [1.16 - 1.30]\* | 0.90 [0.90 - 0.91]\* | 0.96 [0.95 - 0.96]\* | 0.91 [0.87 - 0.94]\* |
| Comorbidity sum score | 1.40 [1.22 - 1.57\*] | 1.50 [1.41 - 1.59]\* | 1.30 [1.23 - 1.37]\* | 2.12 [1.82 - 2.41]\* |

*\*p-value < 0.05*

Appendix Table 3: Influencing factors on longitudinal medication costs across ILD subtypes in complete cases

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | IPF | Fibrosing ILD | Sarcoidosis | Other |
|  | OR [95% CI] | OR [95% CI] | OR [95% CI] | OR [95% CI] |
| Male | 0.36 [0.22 - 0.93]\* | 1.73 [1.27 - 2.20]\* | 2.67 [1.87 - 3.47]\* | 1.53 [1.10 - 1.95]\* |
| Former/Current smoker | 1.29 [0.79 - 1.78] | 0.57 [0.13 - 1.00] | 2.61 [1.90 - 3.33]\* | 1.58 [1.12 - 2.03]\* |
| Age | 0.98 [0.94 - 1.01] | 1.05 [1.03 - 1.07]\* | 1.03 [0.99 - 1.06] | 1.02 [1.00 - 1.04] |
| FVC % pred. At baseline | 1.00 [0.99 - 1.01] | 1.00 [0.99 - 1.01] | 0.99 [0.96 - 1.01] | 1.01 [1.00 - 1.02] |
| Disease duration | 1.09 [0.96 - 1.21] | 0.92 [0.88 - 0.96]\* | 0.94 [0.90 - 0.98]\* | 1.04 [1.00 - 1.08] |
| Comorbidity sum score | 0.99 [0.85 - 1.13] | 1.52 [1.31 - 1.74]\* | 1.60 [1.27 - 1.93]\* | 1.15 [1.01 - 1.29]\* |
| T1 | 4.65 [4.09 - 5.20]\* | 2.22 [1.72 - 2.71]\* | 0.96 [0.58 - 1.34] | 1.56 [1.11 - 2.00]\* |
| T2 | 38.41 [37.86 - 38.95]\* | 11.8 [11.3 - 12.3]\* | 3.51 [3.03 - 3.98]\* | 1.58 [1.12 - 2.03]\* |

*\*p-value* < 0.05

Appendix Table 4: Characteristics of the complete and incomplete cases

|  |  |  |  |
| --- | --- | --- | --- |
|  | Complete cases | Incomplete cases | p-value |
| N | 200 | 71 |  |
| FVC % predicted, mean (SD) | 74.1 (21.0) | 66.7 (18.6) | 0.0078\* |
| DLCO % predicted, mean (SD) | 44.8 (16.1) | 41.5 (17.3) | 0.0741 |
| Mean age, years (SD) | 61.4 (12.7) | 65.2 (13.1) | 0.0132\* |
| Mean time since diagnosis, years (SD) | 4.5 (6.6) | 2.6 (3.5) | 0.0035\* |
| Mean number of comorbidities (SD) | 2.9 (1.6) | 3.1 (1.5) | 0.6328 |
| Male (%) | 133 (66.5) | 46 (64.8) | 0.7936 |
| Female (%) | 67 (33.5) | 25 (35.2) |  |
| ILD subtypes: |  |  | 0.0012\* |
| IPF (%) | 55 (27.5) | 17 (23.9) |  |
| Fibrosing ILD | 32 (16.0) | 0 (0.0) |  |
| Sarcoidosis % | 33 (16.5) | 12 (16.9) |  |
| Other (%) | 80 (40.0) | 42 (59.2) |  |
| Smoking status: |  |  | 0.8187 |
| Current/Former (%) | 127 (63.5) | 44 (62.0) |  |
| Never smoker | 73 (36.5) | 27 (38.0) |  |

*\*p-value < 0.05*

Appendix Table 5: Frequency of comorbid conditions present at baseline by ILD subtype

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | IPF  (N = 71) | PF-ILD  (N = 32) | Sarcoidosis  (N = 45) | Other ILD  (N = 122) |
| Pulmonary Hypertension | 5 (7.0) | 1 (3.1) | 2 (4.4) | 9 (7.4) |
| Arterial hypertension | 36 (50.7) | 9 (28.1) | 20 (44.4) | 46 (37.7) |
| Coronary heart disease | 30 (42.3) | 5 (15.6) | 2 (4.4) | 16 (13.1) |
| Congestive heart failure | 3 (4.2) | 0 (0.0) | 3 (6.7) | 5 (4.1) |
| Other cardiovascular disease | 2 (2.8) | 0 (0.0) | 0 (0.0) | 3 (2.5) |
| Diabetes mellitus | 24 (33.8) | 4 (12.5) | 5 (11.1) | 27 (22.1) |
| Emphysema/COPD | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Lung cancer | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Depression | 6 (8.5) | 2 (6.3) | 5 (11.1) | 7 (5.7) |
| Gastroesophageal reflux disease | 8 (11.3) | 1 (3.1) | 0 (0.0) | 11 (9.0) |
| Renal failure | 4 (5.6) | 2 (6.3) | 1 (2.2) | 5 (4.1) |
| Obstructive sleep apnea | 11 (15.5) | 6 (18.8) | 2 (4.4) | 7 (5.7) |
| Thromboembolism | 1 (1.4) | 0 (0.0) | 3 (6.7) | 3 (2.5) |
| Malignant tumors excluding lung cancer | 4 (5.6) | 1 (3.1) | 1 (2.2) | 1 (0.8) |

*Data are presented as N (%)*